AU2002243230A1 - Piperidine/piperazine-type inhibitors of p38 kinase - Google Patents

Piperidine/piperazine-type inhibitors of p38 kinase

Info

Publication number
AU2002243230A1
AU2002243230A1 AU2002243230A AU4323002A AU2002243230A1 AU 2002243230 A1 AU2002243230 A1 AU 2002243230A1 AU 2002243230 A AU2002243230 A AU 2002243230A AU 4323002 A AU4323002 A AU 4323002A AU 2002243230 A1 AU2002243230 A1 AU 2002243230A1
Authority
AU
Australia
Prior art keywords
piperazine
piperidine
kinase
type inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243230A
Inventor
Sundeep Dugar
Qing Lu
Glenn Mcenroe
John Perumattam
Richland Tester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU2002243230A1 publication Critical patent/AU2002243230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
AU2002243230A 2000-11-20 2001-11-20 Piperidine/piperazine-type inhibitors of p38 kinase Abandoned AU2002243230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25219600P 2000-11-20 2000-11-20
US60/252,196 2000-11-20
PCT/US2001/043824 WO2002046158A2 (en) 2000-11-20 2001-11-20 Piperidine/piperazine-type inhibitors of p38 kinase

Publications (1)

Publication Number Publication Date
AU2002243230A1 true AU2002243230A1 (en) 2002-06-18

Family

ID=22955000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243230A Abandoned AU2002243230A1 (en) 2000-11-20 2001-11-20 Piperidine/piperazine-type inhibitors of p38 kinase

Country Status (8)

Country Link
US (3) US6696443B2 (en)
EP (1) EP1353905B1 (en)
JP (1) JP2004533989A (en)
AU (1) AU2002243230A1 (en)
CA (1) CA2429258A1 (en)
DE (1) DE60125980T2 (en)
ES (1) ES2279837T3 (en)
WO (1) WO2002046158A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533989A (en) * 2000-11-20 2004-11-11 サイオス インコーポレイテッド Piperidine / piperazine type inhibitors of p38 kinase
EP1560582A4 (en) * 2002-10-09 2008-03-12 Scios Inc AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
JP2006527197A (en) * 2003-06-06 2006-11-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア p38 kinase inhibitor composition and method of use thereof
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20080113016A1 (en) * 2004-07-26 2008-05-15 Gary Steven Firestein Method for Prevention or Treatment of Inflammatory Disease
CA2621164A1 (en) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derivative having ppar agonistic activity
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2360376T3 (en) 2006-08-15 2011-06-03 Actelion Pharmaceuticals Ltd. AZETIDINE COMPOUNDS AS AN OREXINE RECEIVER ANTAGONISTS.
ATE496043T1 (en) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
EP2131858A4 (en) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38 inhibitors
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2008150516A1 (en) * 2007-06-04 2008-12-11 The Trustees Of The University Of Pennsylvania A method for testing and screening p38 map kinase modifiers
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CN103420890B (en) * 2012-05-15 2015-06-24 天津药物研究院 3-pyrrole carboxylic acid derivatives, and preparing method and application thereof
CN104718213B (en) * 2012-07-18 2018-02-27 圣母大学 5,5 heteroaromatic anti-infective compounds
EP3033087A4 (en) 2013-08-16 2017-03-15 The J. David Gladstone Institutes Compositions and methods for identifying latently infected cells
CN103664819A (en) * 2013-12-16 2014-03-26 山东汇海医药化工有限公司 Preparation method of ethyl 2-amino-4-methylthiazole-5-carboxylate
CN116942832A (en) 2014-05-16 2023-10-27 归属疗法有限公司 Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus
MX2018000929A (en) 2015-07-31 2018-05-22 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors.
US20180325947A1 (en) 2015-10-27 2018-11-15 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN110382479A (en) 2017-01-20 2019-10-25 辉瑞大药厂 The fluoro- 3- hydroxyl propyl- 2- base ester derivative of carbamic acid 1,1,1- tri- as MAGL inhibitor
EP3571202B1 (en) 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
PT3691620T (en) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN110003244A (en) * 2019-04-23 2019-07-12 沈阳药科大学 Thiazole triazin compound and its application containing trifluoromethyl benzyl
CN111253427A (en) * 2020-03-13 2020-06-09 苏州大学 Application of n-butyl lithium in catalysis of cyanosilicification reaction of aldehyde and silane
CN111303201A (en) * 2020-03-13 2020-06-19 苏州大学 Application of n-butyl lithium in catalysis of cyanogen silicification reaction of ketone and silane
WO2023280911A1 (en) 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69209357D1 (en) * 1991-05-09 1996-05-02 Hoffmann La Roche Substituted carboxylic acid derivatives
FR2680508B1 (en) * 1991-08-20 1995-03-03 Adir NOVEL 1- (ALCOXYBENZYL) PIPERAZINE AMIDE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AU1924099A (en) * 1997-12-18 1999-07-05 Lyonnaise Industrielle Pharmaceutique (Lipha) Piperazine derivatives useful as hypoglycemic agents
NZ508790A (en) * 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
NZ515285A (en) * 1999-05-21 2004-01-30 Scios Inc Indole-type derivatives as inhibitors of p38 kinase
JP2004533989A (en) * 2000-11-20 2004-11-11 サイオス インコーポレイテッド Piperidine / piperazine type inhibitors of p38 kinase

Also Published As

Publication number Publication date
US6696443B2 (en) 2004-02-24
EP1353905B1 (en) 2007-01-10
WO2002046158A3 (en) 2003-08-21
US7214679B2 (en) 2007-05-08
DE60125980T2 (en) 2007-10-25
EP1353905A2 (en) 2003-10-22
JP2004533989A (en) 2004-11-11
CA2429258A1 (en) 2002-06-13
ES2279837T3 (en) 2007-09-01
US20020198214A1 (en) 2002-12-26
WO2002046158A2 (en) 2002-06-13
WO2002046158A9 (en) 2003-05-01
US20070185112A1 (en) 2007-08-09
US20040176382A1 (en) 2004-09-09
DE60125980D1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AU2002243230A1 (en) Piperidine/piperazine-type inhibitors of p38 kinase
AU2001237041A1 (en) Kinase inhibitors
AU2001241927A1 (en) Inhibitors of p38-alpha kinase
IL151104A0 (en) Kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2002234047A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002231166A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
AU2002305260A1 (en) Pyrazole derived kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU8323701A (en) Inhibitors of p38
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002237657A1 (en) Indole-type inhibitors of p38 kinase
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2003268464A1 (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
GB0101686D0 (en) Cyclin dependent kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
AU2001233965A1 (en) Novel cd23 inhibitors
AU2001293869A1 (en) Butenolide and pentenolide derivatives as kinase inhibitors